Bma-LAD-2, an Intestinal Cell Adhesion Protein, as a Potential Therapeutic Target for Lymphatic Filariasis

Area of Science:

• Parasitology
• Molecular Biology
• Drug Discovery

Background:

• Lymphatic filariasis (LF) affects over 70 million people globally, caused by parasitic nematodes.
• Current elimination efforts for LF may require extended timelines and resources.
• New therapeutic targets in adult filarial worms are needed for LF elimination.

Purpose of the Study:

• To evaluate intestinal proteins in adult Brugia malayi worms as potential therapeutic targets.
• To investigate the role of Bma-LAD-2, an immunoglobulin superfamily cell adhesion molecule, in adult worm survival.

Main Methods:

• Short interfering RNA (siRNA) was used to target candidate gene transcripts, including Bma-LAD-2.
• Transcript levels and protein expression of Bma-LAD-2 were quantified post-siRNA treatment.
• Worm motility, microfilaria release, metabolic activity (MTT reduction), and ultrastructure were assessed.

Main Results:

• Bma-LAD-2 siRNA treatment achieved significant knockdown of transcript (70.42%) and protein expression (87.02%).
• Inhibition of Bma-LAD-2 led to reduced worm motility (80%), microfilaria release (93.43%), and MTT reduction.
• Ultrastructural analysis revealed loss of microvilli, mitochondrial damage, and loss of pseudocoelomic fluid in treated worms.

Conclusions:

• Bma-LAD-2 is essential for the survival and reproductive capacity of adult Brugia malayi.
• Bma-LAD-2 represents a promising therapeutic target for drug and vaccine development against lymphatic filariasis.
• The absence of pre-existing IgE antibodies to Bma-LAD-2 in LF patients suggests its safety as a vaccine candidate.